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Aims The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF)
(NCT02072434) study was a multicentre prospective, randomized, open-label, blinded-endpoint evaluation
(PROBE) trial comparing edoxaban with enoxaparin/warfarin followed by warfarin alone in 2199 non-valvular atrial
fibrillation patients undergoing electrical cardioversion and showed comparable rates of bleeding and thromboem-
bolism between treatments. This prespecified ancillary analysis investigated the impact of edoxaban therapy on
treatment satisfaction and utilization of healthcare services.
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Methods
and results
The Perception of Anticoagulant Treatment Questionnaire (PACT-Q2) was completed by study patients on Day 28
post-cardioversion. Higher scores represent greater satisfaction. Healthcare resource utilizations were collected from
randomization to Day 28 post-cardioversion. Data from patients who received at least one dose of study drugs were
analysed. Patients treated with edoxaban were more satisfied than enoxaparin/warfarin in both PACT-Q treatment
satisfaction and convenience scores (P< 0.001 for both). Differences in treatment satisfaction scores were greater in
patients who underwent non-transoesophageal echocardiography (TOE)-guided cardioversion than in patients who
underwent TOE-guided cardioversion. Edoxaban was associated with fewer clinic visits (4.75 visits vs. 7.60 visits;
P< 0.001) and fewer hospital days (3.43 days vs. 5.41 days; P< 0.05). Rates of hospitalizations and emergency room
visits were not significantly different. Overall, edoxaban therapy was estimated to reduce healthcare costs by e107.73,
e437.92, e336.75, and $246.32 per patient in German, Spanish, Italian, and US settings, respectively.
...................................................................................................................................................................................................
Conclusions The convenience of edoxaban therapy over warfarin in patients undergoing cardioversion may provide greater
treatment satisfaction and cost savings to the healthcare system.
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Introduction
EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial
fibrillation (ENSURE-AF) (NCT02072434) was a multicentre, pro-
spective, randomized, open-label, blinded-endpoint evaluation clinical
trial; it compared the efficacy and safety of once-daily edoxaban
60 mg with enoxaparin/warfarin in 2199 patients undergoing electri-
cal cardioversion of non-valvular atrial fibrillation (NVAF).1 Electrical
cardioversion [either transoesophageal echocardiography (TOE)-
guided or non-TOE-guided] can be used in clinical practice to restore
sinus rhythm in patients with AF.2–4 The ENSURE-AF study was the
largest prospective randomized clinical trial of non-vitamin K antago-
nist oral anticoagulation (NOAC) in NVAF patients undergoing elec-
trical cardioversion.1
Edoxaban, a NOAC, is a direct factor Xa inhibitor with linear and
predictable pharmacokinetics indicated for the reduction of the risk
of stroke or systemic embolic event (SEE) in patients with NVAF and
for the treatment of venous thromboembolism.5,6 In the ENSURE-
AF study, the primary endpoint—composite of stroke, SEE, myocar-
dial infarction, and cardiovascular (CV) mortality—occurred in 5
(<1%) patients on edoxaban compared with 11 (1%) on enoxaparin/
warfarin [odds ratio (OR) 0.46, 95% confidence interval (CI) 0.12–
1.43].1 The primary safety endpoint—major and clinically relevant
non-major bleeding—occurred in 16 (1%) patients on edoxaban and
11 (1%) patients on enoxaparin/warfarin (OR 1.48, 95% CI 0.64–
3.55).1 It is unclear if NOAC therapy in electrical cardioversion of AF
has an impact on patient convenience and overall healthcare costs.
Due to the high number of cardioversions performed worldwide,
this aspect of therapy potentially has a significant clinical importance.
The present prespecified subanalysis of ENSURE-AF assessed
treatment convenience/satisfaction, impact of treatment on AF-
related symptoms, healthcare service utilization, and costs associated
with edoxaban vs. enoxaparin/warfarin treatment in NVAF patients
undergoing planned electrical cardioversion.
Methods
Study design
The trial design and primary analyses of ENSURE-AF were previously
reported.1,7 The ENSURE-AF trial was done in compliance with the
Declaration of Helsinki, the International Conference on Harmonisation
(ICH) consolidated Guideline E6 for Good Clinical Practice (CPMP/ICH/
135/95), and applicable regulatory requirements. The protocol and its
amendments were approved by ethics committees or institutional review
boards. In the ENSURE-AF trial, patients with documented NVAF for
>_48 h but <_12 months who were planned for electrical cardioversion
and anticoagulation therapy were included. Patients with NVAF undergo-
ing electrical cardioversion were randomized (1:1) to receive either
once-daily edoxaban 60 mg or enoxaparin/warfarin within each stratum
(i.e. TOE-guided or non-TOE-guided stratum). The dose of edoxaban
was halved to 30 mg for patients who had creatinine clearance of 15–
50 mL/min, low body weight (<_60 kg), or who used P-glycoprotein inhibi-
tors concomitantly. At randomization, all patients were stratified based
on cardioversion approach (TOE or non-TOE), prior experience in tak-
ing anticoagulants at the time of randomization (experienced or naı¨ve),
and whether they met the edoxaban dose reduction criteria.
Consent
All patients provided written informed consent prior to participation in
the study.1
Convenience and treatment satisfaction
Anticoagulant treatment satisfaction was assessed at the end of active
treatment (Day 28) or at follow-up/study discontinuation (up to Day 58)
using the second module of the Perception of Anticoagulant Treatment
Questionnaire (PACT-Q2). All of the items on the PACT-Q2 are an-
swered on a 5-point Likert scale with higher score indicating greater con-
venience or treatment satisfaction.8 PACT-Q2 items are scored along
two domains (convenience and anticoagulant treatment satisfaction) with
a possible score of 100 in each domain (Supplementary material online,
Table S1).8
Atrial fibrillation-related symptoms
Atrial fibrillation-related symptoms were assessed at randomization and
at end of treatment (Day 28) using the European Heart Rhythm
Association classification of AF-related Symptoms (EHRA). The EHRA
assigns patients into four stages based on symptoms and their effects on
daily activities: EHRA I (no symptoms); EHRA II (mild symptoms, normal
daily activity not affected); EHRA III (severe symptoms, normal daily activ-
ity affected); EHRA IV (disabling symptoms, normal daily activity
discontinued).
Healthcare utilization outcomes and cost
assessment
Healthcare resource utilization data—including hospital admissions,
length of stay, and diagnosis; emergency department visits for CV reasons
not resulting in hospitalizations; outpatient physician/nurse visits not asso-
ciated with the study; and number of visits to the investigational site—
were assessed throughout the trial.
Healthcare costs during 28 days of active treatment were compared
between treatment groups. Published cost estimates were applied to
each healthcare utilization outcome that was statistically different be-
tween treatment groups at P< 0.05 (Table 1). Due to the multinational
nature of the study, cost estimates from Germany, Spain, Italy, and the
USA were used to provide a broad perspective of cost differences under
various healthcare systems. Cost estimates were derived from published
sources, supplemented by an ad hoc analysis of a hospital database when
published data were not available (see Table 1).
Statistical analysis
All analyses were performed using the Safety Analysis Set (all randomized
patients who received >_1 dose of study medication). The two domain
What’s new?
• Edoxaban was associated with significantly higher ratings of
convenience and treatment satisfaction than enoxaparin/warfa-
rin in patients undergoing cardioversion.
• The use of edoxaban as anticoagulation pericardioversion sig-
nificantly reduced the number of days spent in the hospital
and the number of clinic visits compared to enoxaparin/warfa-
rin. These reductions in healthcare resource utilization could
result in a saving of e107.73 per patient in Germany and
e437.92 per patient in Spain.
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scores for PACT-Q2 were compared between the treatment regimens
using least squares mean difference scores controlling for cardioversion
approach and anticoagulant experience. The proportion of patients in the
various EHRA classes by treatment regimen at randomization and end of
treatment (Day 28) were compared using the Cochran–Mantel–
Haenszel (CMH) test. Healthcare resource utilization was compared be-
tween the treatment regimens during the active treatment period (from
randomization to Day 28 or study discontinuation visit, whichever was
earlier).
Results
Patient demographic and clinical
characteristics
Demographic and clinical characteristics of 2149 patients in the
Safety Analysis Set were similar in the edoxaban and enoxaparin/war-
farin treatment arms (Table 2). The majority of patients were male
(65.2%) and white (97.7%); mean [standard deviation (SD)] age was
64.2 (10.53) years and mean (SD) CHA2DS2-VASc score was 2.6
(1.44). Most of the patients randomized to edoxaban (91.5%) did not
receive a dose reduction.
Convenience and treatment satisfaction
Treatment convenience and treatment satisfaction were significantly
different between the two treatment arms in the overall study sam-
ple. Overall, patients in the edoxaban group reported significantly
greater treatment convenience and satisfaction vs. enoxaparin/warfa-
rin group as assessed by the PACT-Q2 domain scores (P< 0.001 for
both) (Figure 1). In both TOE and non-TOE subgroups, patients re-
ceiving edoxaban had consistently and significantly higher satisfaction
ratings on both convenience and treatment satisfaction than those
receiving enoxaparin/warfarin. When the analysis was repeated by in-
cluding only patients who did not have any protocol deviations and
completed at least 28 days of study treatment, mean [standard error
....................................................................................................................................................................................................................
Table 1 Unit cost estimates for Germany, Spain, Italy, and USA
Data input Cost estimate Source
Germany
Cost of edoxaban (per pill) e2.59 Lauer-Taxe, February 2017
Cost of warfarin (per pill) e0.24 Lauer-Taxe, February 2017
Hospitalization cost (per diem) e1412.00 Bruggenjurgen et al.9; Supplementary material online, Table S1
Cost of INR (per test) e0.60 AMNOG Dossier, Modul 3 (EBM Ziffer 32113)
Outpatient visit (per visit) e28.86 Bruggenjurgen et al.9; Supplementary material online, Table S1
Spain
Cost of edoxaban (per pill) e1.72 60 mg retail price (minus 7.5% Royal Decree Law 8/2010) Portalfarma Database
Cost of warfarin (per pill) e0.06 Acenocoumarol 2.75 mg/day––retail price (minus 15% Royal Decree Law 8/2010)
Portalfarma Database
Per-diem hospitalization cost e866.23 Cardiology department—eSalud Database 2017
Cost of INR (per test) e25.12 Spanish Hospital Pharmacy Society report (Informe GENESIS de la SEFH, 2012.)
NOACS report (apixaban, dabigatran, rivaroxaban). Prevencio´n de eventos trom-
boembo´licos en pacientes con fibrilacio´n auricular no valvular. Available at: http://
gruposdetrabajo.sefh.es/genesis/
Outpatient visit (per visit) e84.32 Specialist outpatient office—eSalud Spanish Costs Database 2017
Italy
Cost of edoxaban (per pill) e2.09 Ex-factory price IHS Global Insight Database
Cost of warfarin (per pill) e0.07 Codifa.it (coumadin cost per day)
Per-diem hospitalization cost e587.00 Progr 122: Supplemento ordinario N 8 alla Gazzetta ufficiale 28/1/2013: allegato 1
Cost of INR (per test) e26.09 Progr 655 Visita generale ‘Supplemento ordinario N 8 alla Gazzetta Ufficiale, 28/01/
2013, Allegato 3: Prestazioni di assistenza specialistica ambulatoriale’ þ
Prestazione91.49.2 (prelievo sangue venoso) þ 90.75.4 (tempo di protrombina)
Outpatient visit (per visit) e55.78 Progr 627-629-630: Supplemento ordinario N 8 alla Gazzetta ufficiale 28/1/2013:
allegato 3
USA
Cost of edoxaban (per pill) $9.24 per day Wholesale acquisition cost (WAC), Magnuson et al.10
Cost of warfarin (per pill) $0.36 per day WAC, Magnuson et al.10
Per-diem hospitalization cost $2800 per day Ad hoc analysis of hospitalizations of adult AF patients in Premier database (January–
September 2015)
Cost of INR (per test) $20 per test Magnuson et al.10
Outpatient visit (per visit) $60 per visit Magnuson et al.10
AF, atrial fibrillation; INR, international normalization ratio.
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(SE)] treatment convenience score [86.31 (0.53) vs. 82.78 (0.533),
P< 0.001] and treatment satisfaction score [70.58 (0.547) vs. 65.99
(0.549), P< 0.001) remained higher for the edoxaban group than the
enoxaparin/warfarin group.
Edoxaban patients reported higher satisfaction ratings on both
convenience and treatment satisfaction than enoxaparin/warfarin
patients among those with prior experience with anticoagulation
therapy (P< 0.001 for both). Both convenience and treatment satis-
faction ratings were in favour of edoxaban in both patients who were
using vitamin K antagonist (VKA) therapy or NOAC therapy prior to
the study (P<_ 0.005 for all comparisons). Among patients new to an-
ticoagulant therapy, favourable rating for edoxaban vs. enoxaparin/
warfarin was significant for treatment satisfaction (P= 0.004), but not
for convenience (P= 0.065). Edoxaban patients also reported higher
ratings for treatment convenience and treatment satisfaction vs.
enoxaparin/warfarin in centres with time in therapeutic range (TiTR)
>_60% (P< 0.001 for both). For patients who had 2.0 <_ international
normalized ratio (INR) <_ 3.0 during the on-treatment period, TiTR
was defined as the percent of time in therapeutic range
(2.0 <_ INR <_ 3.0) from the first date of 2.0 <_ INR <_ 3.0. Among
patients from centres with TiTR <60%, favourable ratings for edoxa-
ban vs. enoxaparin/warfarin was significant for treatment conve-
nience (P= 0.022) but not for treatment satisfaction (P= 0.076).
Atrial fibrillation-related symptoms
The proportions of patients in each EHRA class at baseline were simi-
lar between the edoxaban group and enoxaparin/warfarin group
(Figure 2). More patients reported no AF symptoms (EHRA I) at end
of treatment (Day 28) than at baseline, irrespective of treatment
group. The proportion of patients in each EHRA class was not signifi-
cantly different between the treatment group overall (P= 0.88) or
between treatment groups in the TOE stratum (P= 0.89) and the
non-TOE stratum (P= 0.86; data not shown).
Healthcare utilization outcomes
The proportion of patients with >_1 hospital admission was similar be-
tween the treatment groups during the 28-day active treatment pe-
riod (Table 3). Patients in the edoxaban group had significantly
shorter hospital stay vs. enoxaparin/warfarin. Most hospital admis-
sions were categorized as CV-related in both arms. The incidence of
bleeding-related hospitalizations, emergency room visits for CV-
related reasons, and the number of outpatient visits did not differ be-
tween treatment groups.
The patients in the enoxaparin/warfarin group visited the investiga-
tional site more often than patients in the edoxaban group by Days
8 and 28 (P< 0.0001 for both; Figure 3). The number of investigational
site visits did not significantly differ between patients who had a
centre-level TiTR of the INR <60% vs. those with a centre-level TiTR
>_60% on Day 8 (P= 0.187) and Day 28 (P= 0.202), for the total sam-
ple (data not shown).
Healthcare costs
Cost estimates for per-diem hospitalization, INR monitoring, outpatient
office visits, and unit drug cost for edoxaban and warfarin were applied
to assess healthcare cost during the 28 days of active treatment.
Based on cost data from the German healthcare setting, using
edoxaban in place of warfarin resulted in a saving of e107.73 per pa-
tient during the 28 days of treatment. Difference in drug acquisition
cost between edoxaban and warfarin was completely offset by
reductions in hospital days, outpatient visits, and INR monitoring.
Similar cost savings were noted in Spanish (-e437.92), Italian
(-e336.75), and US (-$246.32) healthcare settings (Table 4).
Discussion
In this prespecified ancillary analysis of the largest randomized trial
for anticoagulation pericardioversion, patients receiving edoxaban
......................................................................... ..........................................................................
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Table 2 Demographic and clinical characteristics
Edoxaban Enoxaparin/Warfarin
TOE
(n5 570)
Non-TOE
(n5 497)
Total
(n5 1067)
TOE
(n5 577)
Non-TOE
(n5505)
Total
(n5 1082)
Age (years), mean (SD) 64.7 (10.5) 63.6 (10.2) 64.2 (10.4) 64.4 (11.1) 63.7 (10.2) 64.1 (10.7)
Male, n (%) 376 (66.0) 329 (66.2) 705 (66.1) 376 (65.2) 329 (65.1) 705 (65.2)
Race, n (%)
White 551 (96.7) 483 (97.2) 1034 (96.9) 565 (97.9) 500 (99.0) 1065 (98.4)
Black/African–American 1 (0.2) 4 (0.8) 5 (0.5) 1 (0.2) 1 (0.2) 2 (0.2)
Asian 0 2 (0.4) 2 (0.2) 1 (0.2) 2 (0.4) 3 (0.3)
Not indicated 18 (3.2) 8 (1.6) 26 (2.4) 10 (1.7) 2 (0.4) 12 (1.1)
Weight (kg), mean (SD) 90.3 (18.58) 92.6 (18.15) 90.9 (18.38) 90.2 (17.21) 92.3 (20.88) 91.2 (19.03)
CrCl (mL/min), mean (SD) 92.1 (35.83) 96.3 (35.70) 94.1 (35.81) 91.9 (31.98) 96.9 (37.40) 94.3 (34.72)
Dose reduced, n (%)a 48 (8.4) 43 (8.7) 91 (8.5) 49 (8.5) 40 (7.9) 89 (8.2)
CHA2DS2-VASc, mean (SD) 2.7 (1.52) 2.5 (1.45) 2.6 (1.49) 2.7 (1.45) 2.5 (1.33) 2.6 (1.40)
HAS-BLED, mean (SD) 0.9 (0.78) 0.9 (0.77) 0.9 (0.78) 0.9 (0.81) 0.9 (0.76) 0.9 (0.76)
CHA2DS2-VASc, Congestive heart failure, Hypertension, Age >_75, Diabetes mellitus, and prior Stroke or transient ischaemic attack or thromboembolism, Vascular disease,
Age 65–74 years, Sex category; CrCl, creatinine clearance; HAS-BLED, Hypertension, Abnormal renal and liver function, Stroke, Bleeding history or disposition, Labile INR,
Elderly, Drugs or alcohol; INR, international normalized ratio; SD, standard deviation; TOE, transoesophageal echocardiography.
aPatients meeting >_1 of the following criteria: CrCl >_15–<_50 mL/min, low body weight (<_60 kg), or concomitant use of P-gp inhibitors (with the exception of amiodarone).
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consistently reported higher ratings of convenience and treatment
satisfaction with study treatment than patients receiving enoxaparin/
warfarin. The difference in satisfaction ratings is unlikely to be related
to clinical outcomes because AF-related symptom improvement
post-cardioversion and rates of hospitalization were similar between
the edoxaban and enoxaparin/warfarin treatment arms. However,
the duration of hospitalization was significantly shorter in patients re-
ceiving edoxaban vs. enoxaparin/warfarin during the active treatment
period, and edoxaban patients also had fewer visits to the investiga-
tional sites than patients on enoxaparin/warfarin. These differences in
healthcare resource use also suggest that edoxaban could reduce the
overall healthcare cost in patients undergoing electrical cardioversion
of NVAF.
Data assessing treatment convenience/satisfaction and healthcare
cost in NVAF patients undergoing cardioversion are limited. The
ENSURE-AF trial is the largest electrical cardioversion trial in NVAF,
which assessed differences in treatment convenience, treatment sat-
isfaction, and healthcare utilization in patients treated with edoxaban
vs. warfarin/enoxaparin therapy.
Patient preference for NOAC therapy over VKA have been
shown in the PREvention oF thromboembolic events—European
Registry in Atrial Fibrillation (PREFER in AF) previously.11 In the
PREFER in AF registry, patients receiving NOAC therapy reported
higher ratings of convenience and treatment satisfaction than patients
receiving VKA therapy. Considering edoxaban does not require rou-
tine laboratory monitoring, patients are expected not to have to visit
healthcare facilities as frequently as those on VKA therapy; this is es-
pecially the case during the first few weeks of therapy when dose ad-
justment of VKA necessitates closer monitoring. Our findings
corroborate this expectation; we found that edoxaban patients in
ENSURE-AF incurred significantly fewer clinic visits during the first
week of treatment initiation, and statistically significant reduction was
maintained over the 28-day treatment period.
The assigned strategy of cardioversion (TOE- vs. non-TOE-guided
approach) appears to have some impact on treatment satisfaction.
Edoxaban patients undergoing a non-TOE-guided approach show
most pronounced differences in treatment satisfaction ratings relative
to standard enoxaparin/warfarin therapy than patients undergoing
LS Mean (SE)
Convenience
Treatment Satisfaction
Overall
Overall 86.39 (0.52) 82.65 (0.53) 3.75 (2.38, 5.12) <0.0001
0.0014
<0.0001
0.25
0.26
0.08
0.05
0.018
0.96
0.38
0.0002
<0.0001
0.065
0.005
0.0005
0.022
<0.001
<0.0001
0.001
<0.0001
<0.0001
0.0004
<0.0001
0.0003
0.076
<0.0001
3.05 (1.18, 4.92)
4.66 (2.64, 6.68)
4.25 (2.64, 5.86)
2.47 (–0.15, 5.09)
2.82 (0.87, 4.77)
6.57 (2.87, 10.27)
2.26 (4.20, 0.32)
5.00 (7.00, 3.00)
4.76 (3.36, 6.16)
3.20 (1.30, 5.10)
6.58 (4.53, 8.63)
4.74 (3.10, 6.38)
4.83 (2.14, 7.52)
5.32 (3.28, 7.36)
7.28 (3.39, 11.17)
1.80 (–0.19, 3.79)
7.32 (5.27, 9.37)
82.15 (0.68)
82.08 (0.73)
81.29 (0.58)
84.38 (0.96)
81.93 (0.69)
81.85 (1.38)
85.04 (0.70)
79.05 (0.71)
85.20 (0.67)
86.74 (0.73)
85.54 (0.58)
86.85 (0.93)
84.74 (0.71)
88.42 (1.29)
87.30 (0.70)
84.05 (0.74)
70.55 (0.53) 65.80 (0.54)
65.45 (0.69)
65.90 (0.74)
65.60 (0.59)
65.83 (0.98)
65.65 (0.72)
63.90 (1.45)
66.54 (0.71)
65.77 (0.72)
-5 0 5 10
Favours EdoxabanFavours Enoxaparin–Warfarin
15
68.65 (0.69)
72.48 (0.74)
70.34 (0.59)
70.66 (0.96)
70.97 (0.75)
71.18 (1.36)
68.34 (0.72)
72.08 (0.76)
TOE
Non-TOE
Anticoagulant experienced
Anticoagulant naïve
Current VKA user
Current NOAC user
Centre TiTR<60%
Centre TiTR60%
TOE
Non-TOE
Anticoagulant experienced
Anticoagulant naïve
Current VKA user
Current NOAC user
Centre TiTR<60%
Centre TiTR60%
LS Mean Difference
(95% CI) P-value P int
Edoxaban
(n =1067)
Enoxaparin–
Warfarin
(n =1082)
Figure 1 PACT-Q2 scores for the convenience and treatment satisfaction domains. CI, confidence interval; LS, least squares; NOAC, non-vitamin
K antagonist oral anticoagulant; SE, standard error; TiTR, time in therapeutic range; TOE, transoesophageal echocardiography; VKA, vitamin K
antagonists.
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TOE -guided cardioversion. This might be explained by the longer ex-
posure to enoxaparin/warfarin in this strategy (23 vs. 3 days in TOE-
guided patients). This finding may also suggest that inconvenience
might be even more pronounced if therapy with warfarin is pro-
longed. Our study also shows that prior anticoagulant treatment ex-
perience may play an important role in perceived treatment
convenience. Although anticoagulation-naı¨ve patients did not per-
ceive significant differences between edoxaban and enoxaparin/war-
farin in terms of treatment convenience, patients who used NOAC
therapy before the study perceived larger difference in convenience
favouring edoxaban vs. enoxaparin/warfarin therapy, with a non-sig-
nificant trend (Pint = 0.08). Similarly, differences in intensity of INR
monitoring between study centres with TiTR <60% and study cen-
tres with TiTR >_60% may explain the observed difference in results
of treatment satisfaction ratings between edoxaban and standard
therapy in these two settings.
The present study shows that edoxaban regimens reduced utiliza-
tion of healthcare services and costs. The reduction of healthcare
service use and cost are independent of severity of symptoms and
outcome of cardioversion as these outcomes were not significantly
different between edoxaban and enoxaparin/warfarin group. Using
published cost estimates, our analysis estimated that healthcare cost
during the 28 days of oral anticoagulant treatment in patients under-
going electrocardioversion was lower for edoxaban compared with
enoxaparin/warfarin, with a cost savings ranging from e107.73 to
e437.92 per patient depending on healthcare settings. The cost differ-
ence was driven by reduction in the length of hospitalization and the
reduced number of outpatient visits in edoxaban-treated patients.
As the incidence and prevalence of AF are projected to rise over
time, this cost difference due to the reduced length of hospitalization
with edoxaban vs. warfarin may contribute to even greater future re-
source savings from the perspective of the overall healthcare
system.12
The cost of NOAC therapy vs. warfarin in cardioversion has previ-
ously been examined in the X-VeRT study.13 Considering the costs
for drug therapy, monitoring of VKAs, and the cost of cardioversion
procedure and rescheduling of procedure, the X-VeRT study esti-
mated the use of rivaroxaban will result in a savings of £421 and e360
per patient in UK and Italian settings, respectively. Of note, our cost
analysis methodology and objective was different from the X-VeRT
study in that the latter focused on the impact of postponed cardio-
versions and rescheduling of the procedure. Unfortunately, data on
changes of cardioversion scheduling were not captured in the
ENSURE-AF and were not included in our cost analysis. Therefore,
our results may have underestimated the potential cost savings to
healthcare systems.
Limitations
The study has several limitations. First, the study used an open-label
study design. Although clinical endpoint evaluation was blinded to
study investigators in ENSURE-AF, patient-reported outcomes evalu-
ation could not be blinded. Knowledge of treatment may introduce
biases to study results by affecting expectations and may distort the
subjectivity of outcome assessment. In addition, VKA-experienced
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Figure 2 Comparison of EHRA stage change results at baseline and end of treatment. EHRA, European Heart Rhythm Association.
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patients who were not satisfied with VKA previously may be more in-
terested in participating in the study.14 Investigators also may be
more willing to select patients who are good candidates for NOACs
to participate in the trial. As a result, patient selection bias can limit
the generalizability of study results. Furthermore, the study was
a multinational clinical trial enrolling patients receiving clinical care
under different healthcare systems. We applied unit cost from a sin-
gle country to resource use data collected from all patients in
ENSURE-AF. This approach assumes healthcare resource use find-
ings are similar and transferable from one country to another.15
While clinical findings may be transferable from one country to an-
other, economic endpoints such as hospitalizations may be affected
by local clinical practice and resource availability and not generaliz-
able from one country to another.
Conclusion
In conclusion, patients in ENSURE-AF consistently favoured edoxa-
ban over enoxaparin/warfarin in terms of convenience and treatment
satisfaction. Atrial fibrillation-related symptom improvement post-
cardioversion and rates of hospitalization were similar between the
edoxaban and enoxaparin/warfarin treatment arms. The convenience
of edoxaban therapy over warfarin in patients undergoing cardiover-
sion may provide greater treatment satisfaction and healthcare cost
savings.
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..................................... ....................................... ..................................... ........................................
....................................................................................................................................................................................................................
Table 4 Estimated healthcare cost difference in Germany, Spain, Italy, and USA
Germany Spain Italy USA
Edoxaban Warfarin Edoxaban Warfarin Edoxaban Warfarin Edoxaban Warfarin
(n51067) (n51082) (n51067) (n51082) (n5 1067) (n5 1082) (n5 1067) (n5 1082)
Anticoagulant cost
(28-day treatment)
e77 378.84 e7271.04 e51 386.72 e1802.61 e62 440.84 e2120.72 $276 054.24 $10 906.56
Hospitalization cost e193 726.40 e290 278.96 e118 815.20 e178 032.28 e80 536.40 e120 675.46 $384 160.00 $575 624.00
Office visit þ INR monitoring e146 269.70 e242 255.47 e427 354.84 e899 947.01 e282 706.99 e673 233.38 $304 095.00 $657 856.00
Total cost in study cohort e417 374.94 e539 805.47 e597 556.76 e1 079 781.90 e425 684.23 e796 029.56 $964 309.24 $1 244 386.56
Total cost per patient e391.17 e498.90 e560.03 e997.95 e398.95 e735.70 $903.76 $1150.08
Difference per patient -e107.73 -e437.92 -e336.75 -$246.32
INR, international normalization ratio.
..................................................................................................
Table 3 Healthcare resource utilization during the
28-day active treatment period
Edoxaban
(n5 1067)
Enoxaparin/
warfarin
(n51082)
P-value
All-cause hospitalization
Number of admissions 41 41
Patients with >_1
hospitalizations, n (%)
40 (3.7) 38 (3.5) 0.7692
Hospital days, mean (SD) 3.43 (2.69) 5.41 (4.76) 0.0260
Reasons for hospital admissions, n
Bleeding-related 3 2
CV-related 32 31
Arrhythmia 27 25
CHF 2 3
Other CV-related 3 3
Non-CV/bleeding-related 10 8
CV-related hospitalization
Patients with >_1
hospitalization, n (%)
31 (2.9) 29 (2.7) 0.7515
Hospital days, mean (SD) 3.06 (2.46) 5.07 (4.06) 0.0234
CV-related ER visitsa
Patients with >_1 ER visits, n (%) 11 (1.0) 5 (0.5) 0.125
Treatment period from randomization to Day 28 or study discontinuation,
whichever came first.
CHF, congestive heart failure; CV, cardiovascular; ER, emergency room visit; SD,
standard deviation.
aER visits not resulting in hospitalizations or outpatient visits for CV-related
causes not associated with the study protocol.
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